Welcome to BioMarket Group!

Oncology

In this section you will find Therapeutics Diseases & Conditions Oncology market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Cytokine Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 80 companies plus partners who are today developing 99 cytokine drugs in 195 developmental projects in cancer across 20 different targets. In addition, there is 1 suspended drug and another 11 drugs where development has been ceased. Learn More

  2. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  3. Pancreatic Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 385 companies plus partners who are today developing 444 drugs targeting pancreatic cancer in development. across 352 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  4. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  5. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  6. Leukemia Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 456 companies plus partners who are today developing 631 leukemia drugs in 913 developmental projects in cancer across 333 different targets. In addition, there are 8 suspended drugs and another 164 drugs where development has been ceased. Learn More

  7. Radiation Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 322 companies plus partners who are today developing 313 radiation therapy drugs in 692 developmental projects in cancer across 179 different targets. In addition, there are 7 suspended drugs and another 150 drugs where development has been ceased. Learn More

  8. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  9. Renal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More

  10. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  11. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  12. Neuroendocrine Tumors Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 121 companies plus partners who are today developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer across 122 different targets. In addition, there is 1 suspended drug and another 24 drugs where development has been ceased. Learn More

  13. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  14. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  15. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

Oncology

In this section you will find Therapeutics Diseases & Conditions Oncology market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Cytokine Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 80 companies plus partners who are today developing 99 cytokine drugs in 195 developmental projects in cancer across 20 different targets. In addition, there is 1 suspended drug and another 11 drugs where development has been ceased. Learn More

  2. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  3. Pancreatic Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 385 companies plus partners who are today developing 444 drugs targeting pancreatic cancer in development. across 352 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  4. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  5. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  6. Leukemia Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 456 companies plus partners who are today developing 631 leukemia drugs in 913 developmental projects in cancer across 333 different targets. In addition, there are 8 suspended drugs and another 164 drugs where development has been ceased. Learn More

  7. Radiation Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 322 companies plus partners who are today developing 313 radiation therapy drugs in 692 developmental projects in cancer across 179 different targets. In addition, there are 7 suspended drugs and another 150 drugs where development has been ceased. Learn More

  8. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  9. Renal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More

  10. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  11. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  12. Neuroendocrine Tumors Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 121 companies plus partners who are today developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer across 122 different targets. In addition, there is 1 suspended drug and another 24 drugs where development has been ceased. Learn More

  13. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  14. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  15. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction